142 related articles for article (PubMed ID: 33547925)
21. Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.
Jackson AD; Jackson AL; Fletcher G; Doyle G; Harrington M; Zhou S; Cullinane F; Gallagher C; McKone E
Pharmacoeconomics; 2017 Oct; 35(10):1087-1101. PubMed ID: 28699086
[TBL] [Abstract][Full Text] [Related]
22. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.
Bresnick K; Arteaga-Solis E; Millar SJ; Laird G; LeCamus C
BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34857524
[TBL] [Abstract][Full Text] [Related]
23. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
[TBL] [Abstract][Full Text] [Related]
24. Frequency of Cystic Fibrosis Transmembrane Conductance Regulator Variants in Individuals Evaluated for Primary Ciliary Dyskinesia.
Hannah WB; Truty R; Gonzales V; Kithcart GP; Ouyang K; Zeman MK; Li C; Drumm M; Nykamp K; Gaston BM
J Pediatr; 2019 Dec; 215():172-177.e2. PubMed ID: 31610925
[TBL] [Abstract][Full Text] [Related]
25. [Pancreatitis in cystic fibrosis: association with genotype and pancreatic status].
Sojo Aguirre A; Martínez Ezquerra N; Bousoño García C; García Novo MD; Heredia González S; Manzanares López-Manzanares J; Baranda García F; Vázquez Cordero C
An Pediatr (Barc); 2011 Dec; 75(6):401-8. PubMed ID: 21820373
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and genetic analysis of cystic fibrosis transmembrane conductance reseptor-related disease.
Kilinc AA; Alishbayli G; Taner HE; Cokugras FC; Cokugras H
Pediatr Int; 2020 May; 62(5):629-633. PubMed ID: 32003094
[TBL] [Abstract][Full Text] [Related]
27. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry.
Salvatore D; Padoan R; Buzzetti R; Amato A; Giordani B; Ferrari G; Majo F
Pediatr Pulmonol; 2019 Feb; 54(2):150-157. PubMed ID: 30561903
[TBL] [Abstract][Full Text] [Related]
28. Identification of 99% of CFTR gene mutations in Bulgarian-, Bulgarian Turk-, and Roma cystic fibrosis patients.
Petrova G; Yaneva N; Hrbková J; Libik M; Savov A; Macek M
Mol Genet Genomic Med; 2019 Aug; 7(8):e696. PubMed ID: 31245908
[TBL] [Abstract][Full Text] [Related]
29. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
Sosnay PR; Salinas DB; White TB; Ren CL; Farrell PM; Raraigh KS; Girodon E; Castellani C
J Pediatr; 2017 Feb; 181S():S27-S32.e1. PubMed ID: 28129809
[TBL] [Abstract][Full Text] [Related]
30. Cystic fibrosis gene mutations deltaF508 and 394delTT in patients with chronic sinusitis in Finland.
Hytönen M; Patjas M; Vento SI; Kauppi P; Malmberg H; Ylikoski J; Kere J
Acta Otolaryngol; 2001 Dec; 121(8):945-7. PubMed ID: 11813900
[TBL] [Abstract][Full Text] [Related]
31. Natural history of pancreatitis associated with cystic fibrosis gene mutations.
Frulloni L; Castellani C; Bovo P; Vaona B; Calore B; Liani C; Mastella G; Cavallini G
Dig Liver Dis; 2003 Mar; 35(3):179-85. PubMed ID: 12779072
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic contribution of molecular analysis of the cystic fibrosis transmembrane conductance regulator gene in patients suspected of having mild or atypical cystic fibrosis.
Dal'Maso VB; Mallmann L; Siebert M; Simon L; Saraiva-Pereira ML; Dalcin Pde T
J Bras Pneumol; 2013; 39(2):181-9. PubMed ID: 23670503
[TBL] [Abstract][Full Text] [Related]
33. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
34. A novel CFTR mutation found in a Chinese patient with cystic fibrosis.
Li N; Pei P; Bu DF; He B; Wang GF
Chin Med J (Engl); 2006 Jan; 119(2):103-9. PubMed ID: 16454991
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus.
Petrova NV; Kashirskaya NY; Saydaeva DK; Polyakov AV; Adyan TA; Simonova OI; Gorinova YV; Kondratyeva EI; Sherman VD; Novoselova OG; Vasilyeva TA; Marakhonov AV; Macek M; Ginter EK; Zinchenko RA
BMC Med Genet; 2019 Mar; 20(1):44. PubMed ID: 30898088
[TBL] [Abstract][Full Text] [Related]
36. Body mass index and additional risk factors for cancer in adults with cystic fibrosis.
Knotts RM; Jin Z; Doyle JB; Keating C; DiMango E; Abrams JA
Cancer Causes Control; 2022 Dec; 33(12):1445-1451. PubMed ID: 36178608
[TBL] [Abstract][Full Text] [Related]
37. Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al.
Olesen HV; Drevinek P; Gulmans VA; Hatziagorou E; Jung A; Mei-Zahav M; Stojnic N; Thomas M; Zolin A;
J Cyst Fibros; 2020 Mar; 19(2):321-327. PubMed ID: 31680042
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
Mickle JE; Cutting GR
Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
[TBL] [Abstract][Full Text] [Related]
39. Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L.
MacKenzie IER; Paquette V; Gosse F; George S; Chappe F; Chappe V
J Cyst Fibros; 2017 May; 16(3):335-341. PubMed ID: 28392015
[TBL] [Abstract][Full Text] [Related]
40. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
